Journal
CANCER INVESTIGATION
Volume 26, Issue 9, Pages 956-963Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/07357900802132550
Keywords
Colon cancer; adjuvant chemotherapy; oxaliplatin; adjuvant therapy
Categories
Funding
- NCI NIH HHS [U10 CA037377-15, U10 CA037377-16, U10 CA012027-32, U10 CA069974-12, U10 CA069974-10, U10 CA037377-20, U10 CA069651-14, U10 CA069974-11, U10 CA069974-11S2, U10 CA012027-33S1, U10 CA037377-21, U10 CA069651-15, U10CA-37377, U10 CA069651-13, U10 CA012027-33S2, U10 CA012027-37S1, U10 CA012027-30, U10 CA069974, U10 CA012027-35, U10 CA012027-32S1, U10 CA069651, U10 CA012027-34, U10CA-12027, U10 CA037377-19, U10 CA012027-38, U10 CA012027-37, U10 CA037377, U10 CA012027-31, U10 CA037377-18, U10CA-69651, U10 CA069651-12, U10 CA037377-22, U10CA-69974, U10 CA012027, U10 CA012027-31S1, U10 CA012027-33, U10 CA037377-17, U10 CA012027-36, U10 CA069651-11] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [U10CA069651, U10CA069974, U10CA037377, U10CA012027] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
